- Home
- RIGL vs LDI Comparison
RIGL vs LDI Comparison
Compare RIGL & LDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- LDI
- Stock Information
- Founded
- RIGL 1996
- LDI 2010
- Country
- RIGL United States
- LDI United States
- Employees
- RIGL N/A
- LDI N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- LDI Finance: Consumer Services
- Sector
- RIGL Health Care
- LDI Finance
- Exchange
- RIGL Nasdaq
- LDI Nasdaq
- Market Cap
- RIGL 366.5M
- LDI 314.1M
- IPO Year
- RIGL 2000
- LDI 2021
- Fundamental
- Price
- RIGL $17.17
- LDI $1.15
- Analyst Decision
- RIGL Buy
- LDI Sell
- Analyst Count
- RIGL 5
- LDI 3
- Target Price
- RIGL $36.80
- LDI $2.03
- AVG Volume (30 Days)
- RIGL 253.6K
- LDI 1.5M
- Earning Date
- RIGL 03-04-2025
- LDI 03-11-2025
- Dividend Yield
- RIGL N/A
- LDI N/A
- EPS Growth
- RIGL N/A
- LDI N/A
- EPS
- RIGL 0.99
- LDI N/A
- Revenue
- RIGL $179,278,000.00
- LDI $985,646,000.00
- Revenue This Year
- RIGL $14.19
- LDI $40.92
- Revenue Next Year
- RIGL $13.10
- LDI $12.46
- P/E Ratio
- RIGL $17.17
- LDI N/A
- Revenue Growth
- RIGL 54.71
- LDI 5.26
- 52 Week Low
- RIGL $7.48
- LDI $1.14
- 52 Week High
- RIGL $29.82
- LDI $3.23
- Technical
- Relative Strength Index (RSI)
- RIGL 34.02
- LDI 26.88
- Support Level
- RIGL $17.01
- LDI $1.14
- Resistance Level
- RIGL $19.97
- LDI $1.51
- Average True Range (ATR)
- RIGL 1.01
- LDI 0.08
- MACD
- RIGL -0.29
- LDI -0.02
- Stochastic Oscillator
- RIGL 10.65
- LDI 11.92
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.